Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma
MANNHEIM, Germany, Nov. 05, 2024 - Affimed N.V. (Nasdaq: AFMD) (鈥淎ffimed鈥�, or the 鈥淐ompany鈥�), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced three abstracts on two of its innate cell engagers (ICE庐) are accepted for presentation at the 66th ASH Annual Meeting and Exposition taking place December 7-10, 2024, in San Diego, California. Updated clinical results from all 4 cohorts of the run-in phase from the LuminICE-203 study evaluating acimtamig (AFM13) in combination with AlloNK庐 (AB-101) for relapsed/ refractory Hodgkin Lymphoma will be shared in a poster session. An oral presentation will feature clinical results including promising efficacy and safety data from the AFM28 phase 1 dose escalation study in relapsed/refractory acute myeloid leukemia (AML) and poster with preclinical data will highlight the in vitro efficacy of AFM28 in combination with both patient-derived autologous NK cells and healthy volunteer-derived allogeneic NK cells against leukemic blasts.
Details for the oral presentation and poster sessions are as follows:
| Abstract Title | Date / Time / Presenter | Session Name / Location |
| 鈥淚nvestigating the Novel Combination of the Innate Cell Engager (ICE庐) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK庐 in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study鈥� | December 8, 2024 6:00 PM 鈥� 8:00 PM PT Joseph Maakaron, MD Division of Hematology, Oncology and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA |
|
| 鈥淓ngaging Innate Immunity by AFM28, an Innate Cell Engager (ICE庐) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 Study鈥� | December 9, 2024 10:30 AM 鈥� 12:00 PM PT Oral Presentation Time: 11:45 AM PT Pau Montesinos, MD, PhD Hospital Universitari i Polit猫cnic La Fe, Valencia, Spain |
|
| 鈥淭he Bispecific Innate Cell Engager AFM28 Can Leverage AML Patient鈥檚 NK Cells in Addition to Allogeneic NK Cells, Enabling Elimination of CD123+ Leukemic Stem and Progenitor Cells in AML and MDS鈥� | December 9, 2024 6:00 PM 鈥� 8:00 PM PT Nanni Schmitt, Dr. sc. hum. Department of Hematology and Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany |
|